United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary specialty industrial products in the United States and internationally The company offers cosmetic ingredients, including LUBRAJEL, a line of water-based gel formulation for sensory enhancement, lubrication, and texture to personal care products; LUBRAJEL NATURAL for skin moisturizing; LUBRAJEL MARINE that develops natural products using naturally derived polymers; LUBRAJEL OlL NATURAL, which makes luxuriant textures without adding viscosity; LUBRAJEL TERRA, a multifunctional, moisturizing hydrogel products; LUBRASIL II SB, a formulation of LUBRAJEL; LUBRAJEL II XD; B-122, a powdered lubricant used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; and ORCHID COMPLEX, an oil-soluble base for extract of fresh orchids used in fragrance products, such as perfumes and toiletries. Its medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL MGL, a medical lubricant with a lower viscosity medical lubricant; LUBRAJEL LC, LUBRAJEL BA, and LUBRAJEL FA, which are formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. The company's pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial used in urology. Its industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. The company also conducts research and product development of cosmetic ingredients. The company was founded in 1942 and is based in Hauppauge, New York.

United-Guardian, Inc.

Friday, December 12, 2025
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), The Charles Schwab Corp. (SCHW) and Amphenol Corp. (APH), as well as two micro-cap stocks Autoscope Technologies Corp. (AATC) and United-Guardian, Inc. (UG). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Pre-markets Mixed Ahead of Consequential Week of Data
Today's Featured Research Reports
Visa’s shares have outperformed the Zacks Financial Transaction Services industry over the past year (+11.1% vs. -8.7%). The company’s strong market position is underpinned by consistent volume-driven growth, acquisitions and technological leadership in digital payments. Expansion in cross-border volumes, rising transactions and investments in AI and stablecoin infrastructure enhance its future prospects.
Total revenue rose 11% YoY in FY25, along with 13% cross-border growth. A robust financial position with ample liquidity and shareholder returns further supports long-term growth. However, it faces rising client incentives and expenses, which can affect margin growth.
The Zacks analyst expects FY26 adjusted costs to rise nearly 11%. Regulatory pressures and potential legislative changes pose additional risks to its fee structure. While declining cash volumes align with its digital strategy, regional softness warrants monitoring. As such, the stock warrants a cautious stance.
(You can read the full research report on Visa here >>>)
Shares of Charles Schwab have gained +21.8% over the past year against the Zacks Financial - Investment Bank industry’s gain of +37%. The company’s expenses will likely remain elevated amid continued investments in marketing, thus hurting the bottom line. The Zacks analyst expects expenses to witness a CAGR of 7% by 2027. The uncertainty about the performance of the capital markets is another major concern.
Nevertheless, Strategic buyouts (including the deal to buy Forge Global) and branch expansion efforts amid favorable market conditions will likely drive client assets. We estimate total client assets to witness a CAGR of 8.2% by 2027.
Despite the rate cuts so far along with expectations of more, relatively higher rates and an increased focus on repaying high-cost bank supplemental funding balances will support net interest margin (NIM). A solid balance sheet and liquidity position will enable sustainable capital distribution activities.
(You can read the full research report on Charles Schwab here >>>)
Amphenol’s shares have gained +88.5% over the past year against the Zacks Electronics - Connectors industry’s gain of +89.8%. The company benefits from a diversified business model that lowers the volatility of individual end markets and geographies. Its strong portfolio of solutions, including high-technology interconnect products, is a key catalyst.
Expanding spending on both current and next-generation defense technologies bodes well for APH’s top-line growth. Apart from Defense, APH’s prospects ride on strong demand for its solutions across Commercial Air, Industrial, and IT Datacom.
Strong demand for high-speed and power interconnect products, which are critical components in next-gen IT systems, creates long term growth opportunities. APH expects fourth-quarter 2025 earnings to grow between 62% and 65% year over year. Revenues are anticipated to grow in the 39-41% range. However, macroeconomic uncertainty and stiff competition are major concerns.
(You can read the full research report on Amphenol here >>>)
Shares of Autoscope Technologies have underperformed the Zacks Technology Services industry over the past year (-5.5% vs. +20.6%). This microcap company with a market capitalization of $34.02 million is strengthening its position in the evolving ITS market through a next-generation platform built for AI-driven detection, multi-sensor integration and Smart City readiness, supporting future upgrades and broader use cases.
Autoscope Technologies’ shift toward data-centric analytics expands long-term market opportunity and deepens customer integration through recurring software revenues. Federal safety initiatives provide multi-year demand tailwinds across its portfolio, while a new long-duration contract in Georgia enhances visibility and diversifies revenue beyond traditional ITS.
An exclusive distribution agreement with Econolite secures stable market access during product transitions, and a capital-efficient operating model enables sustained innovation without dilution or added leverage.
(You can read the full research report on Autoscope Technologies here >>>)
United-Guardian’s shares have underperformed the Zacks Medical - Products industry over the past year (-34.4% vs. -0.5%). This microcap company with a market capitalization of $27.57 million is facing declining profitability, weakened operating leverage and ongoing instability in the cosmetics segment tied to partner and regional exposure. Limited R&D intensity restricts innovation momentum, and rising working capital needs point to operational strain. Persistent tariffs and geographic risks add uncertainty to margin recovery and long-term earnings visibility.
Nevertheless, United-Guardian’s investment case reflects strengths in expanding its pharmaceutical portfolio, particularly through broader formulary access for Renacidin, alongside stable medical products that support baseline revenues.
Strong cash conversion enables sustained capital returns with a conservative balance sheet. Growing international distribution further reduces concentration risks, while the upcoming Natrajel launch adds a differentiated growth avenue.
(You can read the full research report on United-Guardian here >>>)
Other noteworthy reports we are featuring today include American Express Co. (AXP), BHP Group Ltd. (BHP) and Trane Technologies plc (TT).
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Featured Reports
AmEx (AXP) Aided by Strong Card Member Spending Amid High Costs
Per the Zacks analyst, higher card member spending will drive American Express' U.S. Consumer Services unit. However, growing expenses will impact its profit growth.
Strong HVAC Market Aids Trane Technologies (TT), Costs High
Per the Zacks analyst, Trane Technologies' top-line gains from a strong HVAC Market. Innovative customer-centric solutions are fueling the company's growth. Rising costs remain a concern.
Improving Air Traffic Aid Curtiss-Wright (CW) Amid Labor Shortage
Per the Zacks analyst, Curtiss-Wright is likely to benefit from the improving air traffic. Yet labor shortage result in delays and likely impact operating results.
Strength in Industrial Segment Aids Graco (GGG), Costs Hurt
Per the Zacks analyst, solid traction of Graco's Industrial segment, led by solid demand for liquid finishing systems should drive its growth. However, high operating costs remain concerning.
UDR's Growth Buoyed by Demand Despite Supply and Competition Pressures
Per the Zacks analyst, UDR's strong portfolio, healthy demand and tech-driven efficiencies support growth, though elevated supply in select markets and rising competition may temper rent gains ahead.
Range Resources (RRC) Thrives with Low-Cost Marcellus Gas
Per the Zacks analyst, Range Resources leverages low-cost Marcellus operations and a strong liquids mix to generate resilient cash flows and deliver attractive returns, even amid gas price volatility.
Syfovre and Empaveli Sales Boost Apellis (APLS), Overdependence A Woe
Per the Zacks Analyst, Syfovre and Empaveli sales have been driving revenues for Apellis. However, the company's dependence on these drugs for growth is concerning.
New Upgrades
Investment in Growth Projects to Aid BHP Group (BHP)
The Zacks analyst appreciates BHP's focus on investing in commodities that will help it ride on growing global trends such as decarbonization as well as its efforts to make operations more efficient.
Seagate Gains From (STX) Increasing Data Center and AI Demand
Per the Zacks analyst, Seagate's cost-efficient, high-density, and reliable storage gives it a competitive edge in serving hyperscale cloud providers, social media and AI-driven enterprises.
Sanmina (SANM) Rides on Healthy Demand, Portfolio Strength
Per the Zacks analyst, solid momentum across multiple verticals, including communications networks, cloud and AI infrastructure, will likely drive Sanmina's top line.
New Downgrades
Bath and Body Works (BBWI) Faces Demand Weakness and Margin Pressure
Per the Zacks analyst, BBWI continues to grapple with broad demand softness, heavier promotions and tariff pressures, signaling prolonged margin and growth challenges.
QuidelOrtho (QDEL) Faces Solvency Issues, Competition and Policy Risk
Per the Zacks Analyst, QuidelOrtho (QDEL) faces stiff competition, weak solvency, and reimbursement uncertainties, though strong product sales and lab potential offer cautious optimism.
High Costs and Macro Woes Hurt Toll Brothers' (TOL) Performance
Per the Zacks analyst, Toll Brothers' business is being hurt by ongoing affordability concerns in the housing market. Also, higher land and labor costs are added concerns.
Zacks' Research Chief Picks Stock Most Likely to "At Least Double"
Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.
See Our Top Stock to Double (Plus 4 Runners Up) >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Top Analyst Reports for Visa, Charles Schwab & Amphenol

Wednesday, September 24, 2025
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Oracle Corp. (ORCL), and Cisco Systems, Inc. (CSCO), as well as a micro-cap stock United-Guardian, Inc. (UG). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Pre-markets Modestly Higher Ahead of Late-Week Reports
Today's Featured Research Reports
Broadcom’s shares have outperformed the Zacks Electronics - Semiconductors industry over the past year (+93.1% vs. +51.1%). Broadcom is experiencing strong momentum fueled by growth in AI semiconductors and continued success with its VMware integration. Strong demand for its networking products and custom AI accelerators (XPUs) has been noteworthy. Its AI segment benefits from custom accelerators and advanced networking technology that support large-scale AI deployments with improved performance and efficiency.
However, gross margins in the fiscal fourth quarter are expected to contract sequentially. High debt level is a headwind.
(You can read the full research report on Broadcom here >>>)
Shares of Oracle have outperformed the Zacks Computer - Software industry over the past year (+85.2% vs. +20.2%). Oracle reported first-quarter fiscal 2026 results with total revenue of $14.9 billion, up 12% year-over-year. Cloud revenue grew 28% to $7.2 billion, driven by infrastructure demand. The standout metric was remaining performance obligations (RPO) surging 359% to $455 billion after signing four multi-billion-dollar contracts with three customers.
The company expects $35 billion in capital expenditures for fiscal 2026, primarily for revenue-generating equipment to support massive cloud infrastructure expansion.
(You can read the full research report on Oracle here >>>)
Cisco’s shares have slightly underperformed the Zacks Computer - Networking industry over the past year (+27.8% vs. +27.9%). Cisco’s business model has evolved with subscription revenues accounting for more than half of its total revenues. An increase in recurring revenue base bodes well for investors. Splunk's acquisition enhances its recurring revenue base. The buyout significantly expands Cisco’s portfolio of software-based solutions, contributing more than $4 billion in ARR, and makes it one of the largest software companies in the world.
However, it has been suffering from sluggish networking sales, primarily due to lackluster demand from telecommunication and cable services providers, as well as stiff competition.
(You can read the full research report on Cisco here >>>)
United-Guardian’s shares have underperformed the Zacks Medical-Products industry over the past year (-49.3% vs. +0.6%). The company’s risks include high customer concentration, tariff exposure, and modest R&D spending, limiting pipeline momentum. Profitability pressure from SG&A and investment income decline also warrants monitoring.
However, UG’s first-quarter 2025 performance highlights resilient margin control and strategic diversification amid a 24% revenue decline. Pharmaceutical sales rose 23%, and medical lubricants grew 43%, offsetting cosmetic ingredient headwinds from temporary inventory overhang in China.
(You can read the full research report on United-Guardian here >>>)
Other noteworthy reports we are featuring today include AT&T Inc. (T), Moderna, Inc. (MRNA) and The Kroger Co. (KR).
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Featured Reports
AT&T (T) Rides on Solid Wireless Traction, Fiber Densification
Per the Zacks analyst, AT&T is likely to benefit from a customer-centric business model and solid wireless traction, supported by an integrated fiber expansion strategy and steady 5G deployments.
Moderna's (MRNA) New Launches to Cut COVID Sales Dependency
With COVID vaccine sales declining, Moderna (MRNA) is accelerating development of its non-COVID pipeline. The Zacks Analyst is encouraged by the potential product launches over the next five years.
Coterra Energy (CTRA) to Gain from High Production Volumes
The Zacks analyst believes that Coterra Energy's robust oil and natural gas volumes ensures strong revenue visibility, but weak price realization raises concern.
Kroger's (KR) Strategic Initiatives Appear Encouraging
Per the Zacks analyst, Kroger continues to leverage its customer-first strategy, robust private label portfolio and expanding digital ecosystem to drive shopper engagement and loyalty.
Diversified Revenue Aids Deutsche Bank (DB), Amid Cost Woes
Per the Zacks analyst, Deutsche Bank's diversified revenue mix and shift to stable, capital-light businesses drive growth. Yet elevated expenses, including litigation costs, remain a concern.
Demand for Premium Lens Driving Cooper Companies (COO) Prospects
Per the Zacks analyst, Cooper Companies' growth is fueled by premium lens migration and first-mover advantage in myopia management, offsetting weakness in APAC region and fertility segment.
Spec Strategy Aids Meritage Homes (MTH), Macro Woes Ail
Per the Zacks analyst, Meritage Homes benefits from its solid spec strategy. However, ongoing affordability concerns in the housing market and high mortgage rates remain a concern.
New Upgrades
EchoPark Momentum to Boost Sonic's (SAH) Growth Prospects
A Zacks analyst sees Sonic's EchoPark segment thriving, powered by data-driven inventory and model upgrades, setting up long-term growth amid favorable used-car trends.
Pediatrix Medical (MD) Aided by Portfolio Rejig & Telehealth
Per the Zacks analyst, Pediatrix Medical's portfolio restructuring efforts will continue to improve its business mix and cash level. Its expanding telehealth services will further drive profits.
Acquisitions and Demand from Defense Contracts Boost Oshkosh (OSK)
Per the Zacks Analyst, Oshkosh is expanding its capabilities through strategic acquisitions, while new Department of Defense contracts are driving production growth.
New Downgrades
Pricing Pressure & Integration Risk Weigh on FactSet (FDS)
Per the Zacks analyst, pricing pressure is a headwind for FactSet, lowering its top line and resulting in a loss of market share. Integration risk rises as it pursues a buyout as a growth strategy.
Competition, Flucuating Commodity Price Ail Murphy (MUR)
Per the Zacks analyst Murphy Oil future prospects can be adversely impacted by the fluctuating commodity prices, while competitive industry can affect its profitability.
Weatherproofing Technologies Segment to Hurt Carlisle (CSL)
Per the Zacks analyst, Carlisle is struggling with the poor performance of the Carlisle Weatherproofing Technologies unit due to a slowdown in the residential construction market and project delays.
Quantum Computing Stocks Set To Soar
Artificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.
Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.
Access the Report Free Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AT&T Inc. (T) : Free Stock Analysis Report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Top Research Reports for Broadcom, Oracle & Cisco Systems

Thursday, May 1, 2025
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Salesforce, Inc. (CRM), GE Aerospace (GE) and Booking Holdings Inc. (BKNG), as well as two micro-cap stocks Crimson Wine Group, Ltd. (CWGL) and United-Guardian, Inc. (UG). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Jobless Claims Higher; Q1 Earnings from LLY, MCD & More
Today's Featured Research Reports
Shares of Salesforce have gained +0.7% over the past year against the Zacks Computer - Software industry’s gain of +6.9%. The company is benefiting from a robust demand environment as customers undergo a major digital transformation. Its sustained focus on aligning products with customer needs is driving the top line.
Continued deal wins in the international market are another growth driver. The buyout of Slack has positioned it as a leader in enterprise team collaboration and improved its competitive standing compared to Microsoft Teams. Salesforce’s strategy of continuous expansion of generative AI offerings will help it tap the growing opportunities in the space.
The Zacks analyst estimates suggest that Salesforce revenues are expected to witness a CAGR of 8.9% through fiscal 2025-2028. However, stiff competition and unfavorable currency fluctuations are concerns. Softening IT spending amid ongoing macroeconomic uncertainties may hurt its growth prospects.
(You can read the full research report on Salesforce here >>>)
GE Aerospace’s shares have outperformed the Zacks Aerospace - Defense industry over the past year (+25.6% vs. +6.1%). The company has been witnessing strength in its businesses, driven by robust demand for commercial engines, propulsion and additive technologies. Rising U.S. & international defense budgets, geopolitical tensions, positive airline & airframer dynamics and robust demand for commercial air travel augur well for the company.
GE Aerospace’s portfolio-reshaping actions are likely to unlock values for its shareholders. The company raised its dividend by 28.6% to 36 cents per share in February 2025. For 2025, GE Aerospace expects organic revenues to grow in the low-double-digit range from the year-ago level.
However, it has been dealing with high costs and expenses related to certain projects and restructuring activities, which are likely to affect its margins and profitability. Also, foreign exchange headwinds might be worrying for the company.
(You can read the full research report on GE Aerospace here >>>)
Shares of Booking Holdings have outperformed the Zacks Internet - Commerce industry over the past year (+47.8% vs. +8.2%). The company is benefiting from a favorable environment, owing to growing global leisure travel demand. Substantial improvement in its booking trends remains a major tailwind.
Solid momentum in booked room nights is contributing well to the gross bookings growth. Strong growth in rental car and airline ticket units is a major positive. Also, strong momentum across the merchant, and advertising and other businesses are key growth drivers for BKNG. The growing alternative accommodation business and flight capabilities are tailwinds for the company.
However, sluggishness in its agency business due to the declining trend in agency bookings is a major headwind. Also, geopolitical tensions and market uncertainties remain concerns for the company.
(You can read the full research report on Booking Holdings here >>>)
Crimson Wine’s shares have underperformed the Zacks Beverages - Alcohol industry over the past year (-9.5% vs. -5.7%). This microcap company with a market capitalization of $111.99 million is facing risks which include rising operating costs (more than 8% year over year), reliance on third-party grape sourcing (79% of supply), distributor concentration (30% of sales from one), inventory buildup, limited scalability without capital investment, and pressure from dominant wine producers in the $16-$30 segment.
Modest revenue growth (more than 1%) may limit near-term expansion despite premium positioning. However, Crimson Wine Group owns a diverse portfolio of seven premium estate wineries across key American Viticultural Areas (AVAs) in California, Oregon and Washington, enabling terroir-driven wines and strong brand equity.
Vertical integration and DTC strength (38% of 2024 sales, 65% margin) drive margin stability, while a favorable sales mix lifted 2024 gross profit 4% year over year to $35.1 million. Environmental sustainability, direct consumer engagement and award-winning wines support long-term value.
(You can read the full research report on Crimson Wine here >>>)
Shares of United-Guardian have gained +7.3% over the past year against the Zacks Medical - Products industry’s gain of +10.4%. This microcap company with market capitalization of $36.34 million delivered robust financial results in third-quarter 2024, with a 17.2% year-over-year net sales increase, driven by a 68% surge in cosmetic ingredients sales.
Cosmetics now drive profitability, leveraging strong global demand, offsetting declines in other segments and solidifying the company’s focus on high-margin products. A resilient balance sheet with $2.4 million in cash, minimal liabilities and a consistent quarterly dividend of 25 cents underscore financial stability. Investment income grew 63.5% year over year to $0.3 million, adding flexibility.
Despite an 11% dip in pharmaceutical sales, recovery efforts aim to stabilize the segment. Geographic and product diversification, supported by stable investment income, ensures resilience, positioning United-Guardian to capitalize on growth opportunities in high-demand markets.
(You can read the full research report on United-Guardian here >>>)
Other noteworthy reports we are featuring today include Sony Group Corp. (SONY), Deutsche Bank Aktiengesellschaft (DB) and Fastenal Co. (FAST).
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Digital Transformation and Acquisitions Aid Salesforce (CRM)
Commercial Engines & Services Unit to Aid GE Aerospace (GE)
Booking Holdings Benefits From Steady Leisure Travel Demand
Featured Reports
Strength in Games & Network, Music Segments Benefits SONY
Per the Zacks analyst, Sony is gaining from healthy demand across G&NS and Music units. Also, the company's strategic acquisitions and joint ventures bode well.
Strategic Business Plans Aid Fastenal (FAST), High Costs Ail
Per the Zacks analyst, Fastenal is benefiting from improved customer contract signings and its focus on strategic initiatives. However, increased costs and expenses are marring margins.
Accelerating Non-Trading Revenue Base Aids Nasdaq (NDAQ)
Per the Zacks analyst, Nasdaq is set to grow on its focus toward Market Technology and Information Services businesses. However, increasing expenses weighing on margin expansion is likely a concern.
New Product Launches Aid Zimmer Biomet (ZBH), Debt Woes Ail
The Zacks analyst is impressed with Zimmer Biomet gaining from its innovative product rollouts, with over 50 new products set to be launched in the next 36 months. Yet, mounting debt poses a risk.
Increasing Orders Drive Textron (TXT), Amid Labor Shortage
Per the Zacks analyst, Textron is likely to benefit from increasing orders for its Aviation unit. Yet labor shortage result in delays and likely impact operating results.
International Operations Aid FTI Consulting (FCN), Cost High
Per the Zacks analyst, FTI Consulting's strong international operations make it an excellent partner for global clients, generating continued revenue growth. Rising cost remains a concern.
Nuplazid & Daybue Sales Drive Acadia (ACAD) Amid Competition
Per the Zacks analyst, ACAD is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, the overdependence on Nuplazid and significant competition remain a woe.
New Upgrades
Strong Balance Sheet Position Supports Deutsche Bank (DB)
Per the Zacks analyst, rising deposit balances will strengthen Deutsche Bank's balance sheet. Also, a strong liquidity position aids sustainable capital distribution moves.
Centene (CNC) Rides on Growing Premiums, Strategic Buyouts
Per the Zacks analyst, solid Medicaid business, contract wins and acquisitions continue to drive its premiums and subsequently, revenues. Mergers and acquisitions enhance capabilities.
Investments & Customer Additions Aid Southwest Gas (SWX)
Per the Zacks analyst, Southwest Gas' strategic investment plans will support system improvements and pipe replacement programs. Consistent customer additions will further boost its results.
New Downgrades
SLB to Hurt From Reduced Customer Spending in North America
SLB's North American land operations face challenges due to reduced drilling activity caused by cautious customer spending. Additionally, its significant debt load concerns the Zacks analyst.
Helen of Troy (HELE) Remains Troubled by Reduced Demand
Per the Zacks analyst, HELE is facing challenges due to weakening consumer demand, tighter retailer inventory and ongoing inflationary pressures, all of which are negatively impacting its sales.
EPAM Systems (EPAM) is Hurt by Macroeconomic Headwinds
Per the Zacks analyst, EPAM Systems' near-term prospect looks gloomy due to enterprise customers' cautious spending on IT spending amid the ongoing macroeconomic headwinds.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GE Aerospace (GE) : Free Stock Analysis Report
Salesforce Inc. (CRM) : Free Stock Analysis Report
Fastenal Company (FAST) : Free Stock Analysis Report
Crimson Wine Group Ltd. (CWGL): Free Stock Analysis Report
United-Guardian, Inc. (UG): Free Stock Analysis Report
Booking Holdings Inc. (BKNG) : Free Stock Analysis Report
Sony Corporation (SONY) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Top Analyst Reports for Salesforce, GE Aerospace & Booking Holdings

Monday, December 23, 2024
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including ServiceNow, Inc. (NOW), Advanced Micro Devices, Inc. (AMD) and Sanofi (SNY), as well as two micro-cap stocks Team, Inc. (TISI) and United-Guardian, Inc. (UG). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
ServiceNow’s shares have outperformed the Zacks Computers - IT Services industry over the past year (+56.5% vs. +16.0%). The company has been benefiting from the rising adoption of its workflows by enterprises undergoing digital transformation.
It had 2020 total customers with more than $1 million in annual contract value (ACV) at the end of third quarter, which represents 14% year-over-year growth in customers.ServiceNow had 15 deals greater than $5 million in net new ACV and six deals of more than $10 million. It closed 96 deals greater than $1 million net new ACV.
ServiceNow had 44 new Now Assist customers spending more than $1 million in ACV, including six with more than $5 million and two with more than $10 million. It is also riding an expanding partner base. However, NOW is suffering from persistent inflation, stiff competition and a challenging macroeconomic environment.
(You can read the full research report on ServiceNow here >>>)
Shares of AMD have outperformed the Zacks Computer - Integrated Systems industry over the past two years (+84.8% vs. +73.6%). The company is benefiting from portfolio strength and an expanding partner base. Its portfolio strength is noteworthy, with robust data center demand and accretive acquisitions.
AMD expects fourth-quarter 2024 revenues to be $7.5 billion (+/-$300 million). At the mid-point of its revenue guidance, AMD expects revenues to grow 10% sequentially and 22% year over year, driven by strong growth in the data center and the client segment.
Exiting third-quarter 2024, AMD’s public cloud instances increased 20% year over year to more than 950, with Microsoft, AWS, Uber and Netflix deploying it at scale. Acquisitions of ZT Systems and Silo AI expands AMD’s portfolio. AMD and its partners, including Microsoft, Oracle, DELL, HPE, Lenovo and Supermicro, have instinct platforms in production.
(You can read the full research report on AMD here >>>)
Sanofi’s shares have gained +0.9% over the past year against the Zacks Large Cap Pharmaceuticals industry’s gain of +4.9%. The company’s Dupixent has become the key top-line driver as it enjoys strong demand across all approved indications and geographies. Sanofi possesses a leading vaccine portfolio that drives the top line.
Several new drugs have been launched in the past couple of years that have become significant contributors to Sanofi's top-line growth. Sanofi has also accelerated its mid- and late-stage pipeline this year. It has also been active on the M&A front.
However, generic erosion of Aubagio in all key markets and lower sales from mature products are hurting sales. Other headwinds include the weak performance of diabetes drugs and regular negative pipeline developments.
(You can read the full research report on Sanofi here >>>)
Shares of Team have outperformed the Zacks Building Products - Maintenance Service industry over the past six months (+85.9% vs. -3.4%). This microcap company with market capitalization of $66.92 million demonstrated resilience in third-quarter 2024, with revenue rising 1.96% year over year to $210.8 million, driven by robust demand for Inspection and Heat Treating and steady performance in Mechanical Services.
Operational improvements yielded a $3.2 million operating income, reversing a prior-year loss, while gross margins improved. A significant legal victory vacating a $222 million judgment strengthened financial stability, and investments in advanced technology position the company for growth.
However, high debt, rising interest costs, ongoing net losses, and declining equity reflect financial strain. Litigation risks, stagnant revenue in key segments, and reliance on cost-cutting amid sector volatility further pressure profitability. Team’s diversified, high-margin services provide resilience, but substantial challenges remain.
(You can read the full research report on Team here >>>)
United-Guardian’s shares have outperformed the Zacks Medical - Products industry over the past year (+31.3% vs. +12.7%). This microcap company with market capitalization of $44.47 million delivered robust financial results in third-quarter 2024, with a 17.2% year-over-year net sales increase, driven by a 68% surge in cosmetic ingredients sales.
Cosmetics now drive profitability, leveraging strong global demand, offsetting declines in other segments and solidifying the company’s focus on high-margin products. A resilient balance sheet with $2.4 million in cash, minimal liabilities and a consistent quarterly dividend of 25 cents underscore financial stability. Investment income grew 63.5% year over year to $0.3 million, adding flexibility.
Despite an 11% dip in pharmaceutical sales, recovery efforts aim to stabilize the segment. Geographic and product diversification, supported by stable investment income, ensures resilience, positioning United-Guardian to capitalize on growth opportunities in high-demand markets.
(You can read the full research report on United-Guardian here >>>)
Other noteworthy reports we are featuring today include Fiserv, Inc. (FI), The Cigna Group (CI) and The PNC Financial Services Group, Inc. (PNC).
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Growing Customer Base & Partnerships Aid ServiceNow (NOW)
Strong Product Portfolio & Partner Base Aid AMD's Prospects
Dupixent to Remain Sanofi's (SNY) Key Top-Line Driver
Featured Reports
Fiserv (FI) Gains From Skytef Buyout, Amid High Competition
Per the Zacks analyst, the Skytef acquisition strengthens Fiserv's distribution network and point-of-sale. High competition from other players is an overhang.
Cigna (CI) Benefits from Growing Membership, High Costs Hurt
Per the Zacks analyst, Cigna gains from improving membership leading to solid performances of Evernorth Health Services and Cigna Healthcare businesses. However, rising costs are a concern.
Branch Expansion Aids PNC Financial (PNC) Amid High Costs
Per the Zacks analyst, PNC Financial's branch network expansion across the United States is likely to support its financials. Yet, rising expenses continue to put pressure on its bottom line.
New Customers, Robust Omnipod 5 Sales Aid Insulet (PODD)
The Zacks analyst is bullish about solid new customer gains and increasing volume growth through the U.S. pharmacy channel of Insulet. Also, the robust global uptake of Omnipod 5 seems encouraging.
Industrial Precision Unit Aids Nordson (NDSN), High Debt Ails
Per the Zacks analyst, Nordson's Industrial Precision Solutions segment is driven by solid demand for nonwoven and industrial coating product lines. However, high debt obligation remains a concern.
BlackBerry (BB) Gains from Strength in IoT & Secure Comms
Per the Zacks analyst, momentum in the Secure communications and IoT businesses along with sale of Cylance unit bode well. However, tough backdrop in the automotive space is concerning.
Delek (DK) Bolsters Financial Position Through Asset Sale
The Zacks analyst believes that proceeds from Delek US Holdings' retail division sale have strengthened its balance sheet but is worried over the weak refining margins weighing on profitability.
New Upgrades
Sprouts Farmers' (SFM) Omnichannel Offering to Propel Sales
Per the Zacks analyst, Sprouts Farmers' assortment of better-for-you products, focus on providing hassle-free shopping through omnichannel offering & a network of fresh distribution centers bode well.
Investments, Appalachian Assets Aid National Fuel Gas (NFG)
Per the Zacks analyst, National Fuel Gas' systematic investment to further strengthen its midstream operations and strong presence in the Appalachian region will boost its performance.
Solid Retail Segment to Fuel Urban Outfitters' (URBN) Sales
Per the Zacks analyst, Urban Outfitters gains from its strong Retail segment, which saw a 3.2% increase in total net sales in the third quarter, with comparable net sales rising by 1.5%.
New Downgrades
Regulations, Seasonality of Business Ail MDU Resources (MDU)
Per the Zacks analyst, MDU Resources' operations are likely to be adversely impacted by government regulations. Seasonality of business operations can reduce demand and lower earnings.
Spectrum Brands (SPB) Struggles With Multiple Headwinds
Per the Zacks analyst, Spectrum Brands has been grappling with geopolitical and macroeconomic uncertainty for a while. The company reported soft bottom-line results in fourth-quarter fiscal 2024.
Lingering Macro Risks & High Costs Ail Mohawk's (MHK) Growth
Per the Zacks analyst, higher mortgage rates, sticky inflation and political uncertainties are marring the prospects of Mohawk. Also, high labor, materials and freight costs add to the headwinds.
Zacks Naming Top 10 Stocks for 2025
Want to be tipped off early to our 10 top picks for the entirety of 2025?
History suggests their performance could be sensational.
From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2025. Don’t miss your chance to get in on these stocks when they’re released on January 2.
Be First to New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report
Sanofi (SNY) : Free Stock Analysis Report
Advanced Micro Devices, Inc. (AMD) : Free Stock Analysis Report
The PNC Financial Services Group, Inc (PNC) : Free Stock Analysis Report
Cigna Group (CI) : Free Stock Analysis Report
ServiceNow, Inc. (NOW) : Free Stock Analysis Report
Team, Inc. (TISI) : Free Stock Analysis Report
Fiserv, Inc. (FI) : Free Stock Analysis Report
United-Guardian, Inc. (UG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Top Research Reports for ServiceNow, AMD & Sanofi

For Immediate Release
Chicago, IL – July 11, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo Nordisk A/S NVO, AbbVie Inc. ABBV, AstraZeneca PLC AZN, Air T, Inc. AIRT and United-Guardian, Inc. UG.
Here are highlights from Wednesday’s Analyst Blog:
Top Stocks Reports for Novo Nordisk, AbbVie and AstraZeneca
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S, AbbVie Inc. and AstraZeneca PLC, as well as two micro-cap stocks, Air T, Inc. and United-Guardian, Inc. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Novo Nordisk shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+84.5% vs. +34.3%). The Zacks analyst believes that the company’s diabetes and obesity drugs segments have been driving business growth, and the company is also gearing up to buy Cardior to help diversify.
Yet, intense rivalry in the obesity sector threatens Novo Nordisk’s market share. Patent expiry and pricing pressure across the diabetes market also remain a major concern.
(You can read the full research report on Novo Nordisk here >>>)
AbbVie’s shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+23.9% vs. +34.3%). The Zacks analyst believes that the company faces several near-term headwinds like Humira’s biosimilar erosion, increasing competitive pressure on Imbruvica and decreased demand for fillers in international markets.
Yet, high costs and expenses related to projects and restructuring activities have remained as causes of concern.
(You can read the full research report on AbbVie here >>>)
Shares of AstraZeneca have underperformed the Zacks Large Cap Pharmaceuticals industry over the past two years (+14.8% vs. +38.9%). Per the Zacks analyst, the company’s diabetes franchise faces stiff competition while the respiratory unit is being hurt by pricing pressure.
Yet, a massive global presence, diverse product portfolio, external acquisitions and strategic collaborations to boost its pipeline are going to aid. Also, key drugs like Lynparza, Tagrisso, Imfinzi, Fasenra, Ultomiris and Farxiga should keep driving revenues.
(You can read the full research report on AstraZeneca here >>>)
Air T’s shares have outperformed the Zacks Transportation – Air Freight and Cargo industry over the past six months (+58.4% vs. -6.3%). The Zacks analyst believes that wise acquisitions, higher administrative fees and diversification across four segments have helped drive Air T’s growth in recent months. The WASI acquisition enhances service offerings and geographic reach, contributing to revenue growth. Equity investments and effective cost management bolster financial stability.
However, declining profit margins, high debt levels, negative cash flows, and sector-specific risks and operational losses remain major headwinds.
(You can read the full research report on Air T here >>>)
United-Guardian’s shares have outperformed the Zacks Medical – Products industry over the past year (+15.1% vs. -3.1%). The Zacks analyst believes that discontinuation of low-growth industrial products, focus on higher-margin segments, market strength in cosmetic ingredients and medical lubricants and being supported by a global customer base have helped grow UG’s business.
However, a significant reserve of slow-moving and obsolete inventory, concentration of key customers and supply chain vulnerabilities remain causes for concern.
(You can read the full research report on United-Guardian here >>>)
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN) : Free Stock Analysis Report
Novo Nordisk A/S (NVO) : Free Stock Analysis Report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
United-Guardian, Inc. (UG): Free Stock Analysis Report
Air T, Inc. (AIRT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	13.47 20.83
Price/Sales	2.64 0.79
P/B	2.51 1.93
P/FCF	17.11 19.15

Indicator	TTM Median
ROE	26.67 13.73
ROA	23.08 5.96
ROI	0.00 9.24
Net Worth	0.03 1.42
Quick Ratio	6.16 0.81
Current Ratio	7.04 1.34

Indicator	TTM Median
Net Profit Margin	33.33 6.65
Operating Margin	33.33 9.72
Gross Margin	44.44 34.34
Return on tangible equity	26.67 25.93

Indicator	TTM Median
EPS	0.06 0.53
EPS Forecast	0.00 0.45
Revenue	2.00M 147.00M
Gross Profit	1.00M —
EBITDA	0.00 —

United-Guardian, Inc.

TTM metrics for the latest quarter under IFRS and their historical dynamics

Valuation

Debts

Efficiency

Other ratios

Revenue